Back

Epiproteomic control of the epitranscriptome drives cortical neurogenesis

Borisova, E.; Cuthill, K. J.; Dannenberg, R.; Koch, J.; Nowaczyk, J.; Schaub, T.; Schwark, M.; Kastelic, N.; Kupryianchyk-Schultz, I.; Kirchner, M.; Pentimalli, T. M.; Fokkens, T. J.; Stein, F.; Dietrich, C.; Quedenau, C.; Borodina, T.; Schwefel, D.; Conrad, T.; Rybak-Wolf, A.; Rajewsky, N.; Mertins, P.; Haberkant, P.; Lorenz, S.; Brose, N.; Kawabe, H.; Tarabykin, V.; Ambrozkiewicz, M. C.

2025-04-09 cell biology
10.1101/2025.04.09.646620 bioRxiv
Show abstract

Neurological conditions are the leading cause of ill health worldwide. Here, we show that the neurodevelopmental disorder-associated ubiquitin ligase UBE3C regulates the cellular composition of the murine cerebral cortex and human brain organoids, with its loss favoring neurogenesis and suppressing glial fate. Using genetic complementation, we demonstrate that disease-associated UBE3C mutations alter its autoubiquitination activity and disrupt cortical lamination. Proteomic profiling of UBE3C-deficient forebrains and organoids identifies Cbll1 as a UBE3C substrate, and we show that the UBE3C-Cbll1 duo drives N6-methyladenosine (m6A) mRNA methylation. Hyperactivation of m6A writers in UBE3C-deficient neural progenitors impairs cell cycle exit, a defect reversible in vivo by the METTL3 inhibitor STM2457. Our findings uncover an epiproteomic mechanism controlling m6A-mediated gene expression and define a regulatory axis linking ubiquitin signaling to epitranscriptomic control of neural fate. This work provides a mechanistic framework for understanding neurodevelopmental disorders and highlights potential therapeutic strategies.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.